Report an error
Spotted something inaccurate in “Aficamten Wins Global Approval as Second Cardiac Myosin Inhibitor for HCM”? Tell us what’s wrong and we’ll check it against the original source.
This form is for factual corrections. We read every report but cannot reply individually.